uniQure N.V Total Liabilities
uniQure N.V total liabilities. Based on the latest financial reports, uniQure N.V (UQ1) has total liabilities worth €629.36 Million EUR (≈ $735.79 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check uniQure N.V liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of uniQure N.V (2016–2025)
Total liabilities of uniQure N.V from 2016 to 2025. This chart illustrates how uniQure N.V's total liabilities have evolved over time, based on quarterly financial data. Explore uniQure N.V (UQ1) long-term investment share to see how much of total assets are deployed in long-term investments.
uniQure N.V Competitors by Total Liabilities
The table below lists competitors of uniQure N.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sk Gas
KO:018670
|
Korea | ₩4.69 Trillion |
|
ShenZhen QiangRui Precision Technology Co. Ltd.
SHE:301128
|
China | CN¥1.75 Billion |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
USA | $28.59 Million |
|
Qinchuan Machine Tool & Tool Group Share Co Ltd
SHE:000837
|
China | CN¥4.51 Billion |
|
Zhe Jiang Dali Technology Co Ltd
SHE:002214
|
China | CN¥773.41 Million |
|
Insperity Inc
NYSE:NSP
|
USA | $2.13 Billion |
|
Flowers Foods Inc
NYSE:FLO
|
USA | $2.88 Billion |
|
Orange Belgium SA
BR:OBEL
|
Belgium | €3.09 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down uniQure N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see UQ1 asset base.
Liquidity & Leverage Metrics
uniQure N.V Total Liabilities Ratios Explained
uniQure N.V total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how uniQure N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for uniQure N.V (2016–2025)
The table below shows the annual total liabilities of uniQure N.V from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €626.01 Million ≈ $731.87 Million |
+11.13% |
| 2024-12-31 | €563.29 Million ≈ $658.54 Million |
-9.73% |
| 2023-12-31 | €624.02 Million ≈ $729.54 Million |
+172.55% |
| 2022-12-31 | €228.96 Million ≈ $267.67 Million |
+7.29% |
| 2021-12-31 | €213.40 Million ≈ $249.49 Million |
+121.17% |
| 2020-12-31 | €96.49 Million ≈ $112.81 Million |
-23.16% |
| 2019-12-31 | €125.57 Million ≈ $146.81 Million |
+33.16% |
| 2018-12-31 | €94.30 Million ≈ $110.25 Million |
-21.60% |
| 2017-12-31 | €120.28 Million ≈ $140.63 Million |
-5.01% |
| 2016-12-31 | €126.63 Million ≈ $148.05 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more